구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Certolizumab |
Overview Company | UCB Pharma |
Overview Modality | ANTIBODY |
Overview Target | Chronic Nonbacterial Osteomyelitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers linked to clinical remission in RA is currently a challenge |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.. Crohn's disease is an inflammatory bowel disease (IBD) that can extend to any part of the gut. Many people with Crohn's disease fail to reach and maintain remission using conventional therapies. Biologic therapies with different mechanisms have advanced rapidly over recent decades. Comparative d… |
Clinical Safety signal | Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.. Crohn's disease is an inflammatory bowel disease (IBD) that can extend to any part of the gut. Many people with Crohn's disease fail to reach and maintain remission using conventional therapies. Biologic therapies with different mechanisms have advanced rapidly over recent decades. Comparative d… |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT00845663 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Certolizumab |
Overview Company | UCB Pharma |
Overview Modality | ANTIBODY |
Overview Target | Chronic Nonbacterial Osteomyelitis |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Established |
Overview Approval status | Approved (flag incomplete) |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers linked to clinical remission in RA is currently a challenge |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.. Crohn's disease is an inflammatory bowel disease (IBD) that can extend to any part of the gut. Many people with Crohn's disease fail to reach and maintain remission using conventional therapies. Biologic therapies with different mechanisms have advanced rapidly over recent decades. Comparative d… |
Clinical Safety signal | Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.. Crohn's disease is an inflammatory bowel disease (IBD) that can extend to any part of the gut. Many people with Crohn's disease fail to reach and maintain remission using conventional therapies. Biologic therapies with different mechanisms have advanced rapidly over recent decades. Comparative d… |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Program phase | APPROVED |
Clinical Trial ref | NCT00845663 |
추천 비교
추천 비교